Clinical

Two story lines predominated renal news in 2020: coronavirus disease 2019's effect on the kidneys and the overwhelming benefits of sodium-glucose cotransporter 2 inhibitors for those with chronic kidney disease and type 2 diabetes.

The review of 32 studies revealed that biologic treatment tended to favor patients with allergic bronchopulmonary aspergillosis (ABPA) and asthma rather than those with cystic fibrosis (CF).

This year’s top 5 most-read stories in lung cancer were overrun by non–small cell lung cancer drug trial results and FDA action.

A study from Denmark found that low health literacy was not a risk factor for mortality in patients with chronic obstructive pulmonary disease (COPD) compared with the general population and patients with other chronic conditions.

Researchers sought to gain a better understanding of the relationship between genetic mutations in metastatic colon cancer (mCRC), advanced disease, and locations of primary tumors.

The FDA has approved Margenza (margetuximab-cmkb) plus chemotherapy as a treatment option for adults with HER2-postive advanced breast cancer.

Researchers explored the risk of cardiovascular disease (CVD) as it relates to factors like excess weight, disease evolution time, and clinical activity.

As a neurodegenerative disease, secondary progressive multiple sclerosis (SPMS) may lead to a degradation of cognition skills as the disease progresses.

Researchers review pulmonary function testing measures that span 4 categories that can assess the respiratory muscle dysfunction that happens in diseases like spinal muscular atrophy (SMA).

Researchers found abnormal coherence patterns in survivors of childhood polio.

The analysis reviewed the safety and efficacy among patients in Japan to confirm the findings of the overall study population.

Giving patients icosapent ethyl, or Vascepa, led to a 52% reduction of the total patient-reported symptom outcome prevalence score as compared with a 24% decline for outpatients who received usual care.

Physicians will soon have a more complex set of options when treating patients with multiple myeloma (MM), but the authors of a new review article argued clinicians will need to take a pragmatic approach.

Both clinical and physician-based factors play a role in the risk of a patient with hematologic malignancies ending up in the ICU.

A new study indicates that an analysis of serum and cerebrospinal fluid cytokine levels can identify multiple sclerosis and its forms.

A new meta-analysis finds high rates of efficacy and high rates of toxicity in multiple myeloma patients treated with B-cell maturation agent (BCMA)-targeted chimeric antigen receptor (CAR)- T cells.

A new study may help clear up questions about the superiority of venetoclax with hypomethylating agents in patients who are deemed to be at high risk of treatment-related mortality.

Friction of surgical instruments has the greatest association with incisional Descemet membrane detachment (DMD) during cataract surgery, according to results of a case series published in JAMA Ophthalmology.

The analysis, published in Cephalalgia, found that more than 50% of patients exhibited reversion from chronic migraine to episodic migraine after week 12 of the double-blind treatment phase.

Clarence Moore, PharmD, BCPS, BCOP, assistant professor at Shenandoah University in Ashburn, Virginia, discusses how stem cell therapy and heart health can help patients manage beta thalassemia.

Scientists in Japan describe how a population of spinal cord astrocytes appear to have a role in producing pain hypersensitivity.

A recent study found that patients with both chronic obstructive pulmonary disease (COPD) and diabetes using oral hypoglycemic agents had lower risks of severe exacerbations than controls.

Circulating tumor DNA (ctDNA) has a host of benefits in treating and managing patients with early-stage disease, noted Alexey Aleshin, MD, senior medical director of Oncology at biotech giant Natera.

A review published earlier this year examines the rationale and evidence for using a multidrug approach in pulmonary arterial hypertension (PAH).

A variety of factors contributed to discontinuation rates in FIDELIO-DKD, said George Bakris, MD, professor of medicine and director of the American Heart Association Comprehensive Hypertension Center at the University of Chicago Medicine.